Overview
“PeptiGrowth Inc. headquartered in Japan, stands as the world’s pioneer company in developing and supplying a series of “Synthetic Peptide Growth Factors” with equivalent or superior functionality compared to conventional recombinant growth factors by leveraging the proprietary technology of its shareholder, PeptiDream Inc., called Peptide Discovery Platform Systems (PDPS). These cyclic peptides ensure consistent quality and activity across batches as they are entirely chemically synthesized and are free from animal component contaminations, making them suitable for use in regenerative medicine and cell therapy applications. Additionally, the synthetic peptide growth factors exhibit exceptionally high stability in solution, eliminating the need for frequent cell culture media exchanges and thus reducing overall media costs. PeptiGrowth can supply the GMP-grade peptides at highly competitive prices, addressing various challenges associated with conventional growth factors, such as high costs, instability, batch-to-batch variation, and the difficulty of GMP control.
Currently, PeptiGrowth has launched nine products: Hepatocyte Growth Factor alternative peptide, BDNF alternative peptide, VEGF alternative peptide, Wnt3a alternative peptide, Noggin-like peptide, synthetic EGF, TGF-β1 inhibitor, BMP7 selective inhibitor, and BMP4 selective inhibitor. Additional products will be launched soon, such as TPO, bFGF, KGF, PDGF, IL-15, IL-2, SCF etc. For more information, please visit https://peptigrowth.com/en/
Company News
